OSAKA, Japan & CAMBRIDGE, Mass. - Tuesday, 20. June 2023 AETOSWire Print 

Pivotal Phase 3 Findings with HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] Showed a Clinically Significant Reduction in Relapse Rate as well as a Delayed Time to Relapse Compared to Placebo When Used as a Maintenance Therapy in Adult Patients with CIDP
ADVANCE Clinical Program Reflects Takeda’s Commitment to Investigating Immunoglobin (IG) Therapy for Patients with Neuroimmunological Disorders
 

(BUSINESS WIRE) -- Takeda (TSE:4502/NYSE:TAK) today announced full results from the pivotal Phase 3 ADVANCE-CIDP 1 clinical trial investigating HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] as maintenance therapy in adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Results showed a clinically significant reduction in relapse ... Read more »

Up to 40% of people who reached the highest two doses of survodutide (BI 456906) achieved a weight loss of at least 20%1
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite2
Detailed data were presented at the 2023 American Diabetes Association’s 83rd Scientific Sessions
 

(BUSINESS WIRE) -- Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) today announced additional data demonstrating superior efficacy with survodutide (also known as BI 456906) versus placebo in people with overweight or obesity without type 2 diabetes after 46 weeks of treatment.1 The findings were presented at the 2023 American Diabetes Association’s 83rd Scientific Sessions in San Diego, CA, U.S.

The Phase II study included two analyses: planned (assigned dose at randomization, which was also the primary endpoint) and actu ... Read more »

(BUSINESS WIRE) -- ODDITY Tech Ltd. (“ODDITY”), a consumer tech platform that is built to transform the global beauty and wellness market, today announces that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its Class A ordinary shares. ODDITY has applied to list its Class A ordinary shares on the Nasdaq Global Select Market under the ticker symbol “ODD.” The number of shares to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, and Allen & Company LLC are acting as lead book-running managers for the proposed offering. BofA Securities, Barclays Capital Inc., Truist Securities, ... Read more »